Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.50.

Several equities analysts have recently weighed in on IMRX shares. Oppenheimer restated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a report on Sunday, April 19th. Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Immuneering in a report on Tuesday, May 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Immuneering in a report on Monday, March 9th.

Institutional Investors Weigh In On Immuneering

Several institutional investors have recently modified their holdings of IMRX. Jane Street Group LLC purchased a new stake in shares of Immuneering during the first quarter valued at $32,000. Geode Capital Management LLC boosted its position in shares of Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Immuneering during the second quarter valued at $90,000. Bridgeway Capital Management LLC boosted its position in shares of Immuneering by 57.9% during the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after buying an additional 35,000 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in shares of Immuneering during the second quarter valued at $215,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $3.92 on Friday. Immuneering has a 1-year low of $1.66 and a 1-year high of $10.08. The business has a fifty day moving average price of $5.21 and a 200-day moving average price of $5.46. The company has a market capitalization of $253.62 million, a PE ratio of -3.35 and a beta of 0.38.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.09. On average, sell-side analysts anticipate that Immuneering will post -1.12 earnings per share for the current fiscal year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.